Skip to main content

Advertisement

SpringerLink
Log in

Isolated Full Donor T-Cell Chimerism After Haploidentical TCRαβ/CD19 Depleted HSCT Maintains Remission of Familial HLH

  • Letter to Editor
  • Published:
Journal of Clinical Immunology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Data Availability

Data are available on request subject to privacy or other restrictions.

References

  1. Hartz B, Marsh R, Rao K, Henter JI, Jordan M, Filipovich L, et al. The minimum required level of donor chimerism in hereditary hemophagocytic lymphohistiocytosis. Blood. 2016;127:3281–90. https://doi.org/10.1182/blood-2015-12-684498.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Greental Ness Y, Kuperman AA, Stein J, Yacobovich J, Even-Or E, Zaidman I, et al. Improved transplant outcomes with myeloablative conditioning for hemophagocytic lymphohistiocytosis in HLA-matched and mismatched donors: a national multicenter retrospective study. Bone Marrow Transplant [Internet]. Springer US; 2021; 56:2088–96. https://doi.org/10.1038/s41409-021-01290-1

  3. Sieni E, Cetica V, Hackmann Y, Coniglio ML, Da Ros M, Ciambotti B, et al. Familial hemophagocytic lymphohistiocytosis: When rare diseases shed light on immune system functioning. Front Immunol. 2014;5:1–19.

    Article  CAS  Google Scholar 

  4. Ghosh S, Carmo M, Calero-Garcia M, Ricciardelli I, Bustamante Ogando JC, Blundell MP, et al. T-cell gene therapy for perforin deficiency corrects cytotoxicity defects and prevents hemophagocytic lymphohistiocytosis manifestations. J Allergy Clin Immunol [Internet]. Elsevier Inc.; 2018; 142:904–913.e3. https://doi.org/10.1016/j.jaci.2017.11.050

  5. Weißert K, Ammann S, Kögl T, Dettmer-Monaco V, Schell C, Cathomen T, et al. Adoptive T cell therapy cures mice from active hemophagocytic lymphohistiocytosis (HLH). EMBO Mol Med. 2022;14(12):e16085. https://doi.org/10.15252/emmm.202216085.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

Florence HLH consortium:

Beatrice Martini3

Rosalba Santoro4

Aurora Chinnici2

Linda Beneforti2

Elisa Allegro5

Franco Bambi5

Francesca Brugnolo5

Daniela Cuzzubbo2

Stefano Ermini5

Stefano Frenos2

Francesco Pegoraro2,4

Maria Chiara Sanvito2

Veronica Tintori2

Irene Trambusti2

Claudio Favre2

4Department of Health Sciences, University of Florence, Florence, Italy

5Department of Immunohematology, Transfusion Medicine and Laboratory, Meyer Children’s Hospital IRCCS, Florence, Italy

Author information

Authors and Affiliations

  1. Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, Florence, Italy

    Filippo Consonni

  2. Centre of Excellence, Division of Pediatric Oncology/Hematology, Meyer Children’s Hospital IRCCS, Florence, Italy

    Filippo Consonni, Maria Luisa Coniglio, Elena Sieni & Eleonora Gambineri

  3. Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, Florence, Italy

    Eleonora Gambineri

Authors
  1. Filippo Consonni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maria Luisa Coniglio
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Elena Sieni
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Eleonora Gambineri
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

Florence HLH consortium

  • Beatrice Martini
  • , Rosalba Santoro
  • , Aurora Chinnici
  • , Linda Beneforti
  • , Elisa Allegro
  • , Franco Bambi
  • , Francesca Brugnolo
  • , Daniela Cuzzubbo
  • , Stefano Ermini
  • , Stefano Frenos
  • , Francesco Pegoraro
  • , Maria Chiara Sanvito
  • , Veronica Tintori
  • , Irene Trambusti
  •  & Claudio Favre

Contributions

FC and ES wrote the original manuscript. Material preparation, data collection, and analysis were performed by MLC, FC, and BM. RS, AC, and LB arranged the figures. ES, FP, and IT provided pre-transplant clinical care. EA, FBr, FBa, and SE performed TCRαβ+/CD19+ depletion. EG, DC, SF, MCS, and VT performed transplant and provided post-transplant clinical care. ES, EG, and CF designed the study and supervised the work. All authors read and approved the final version of the manuscript. ES and EG equally contributed to this work and share senior authorship.

Corresponding author

Correspondence to Eleonora Gambineri.

Ethics declarations

Ethics Approval/Consent to Participate/Consent for Publication

The case history and biological material was obtained with informed consent in accordance with the Declaration of Helsinki. No ethics approval was required for this.

Conflict of Interest

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Elena Sieni and Eleonora Gambineri contributed equally to this work and share senior authorship.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Consonni, F., Coniglio, M.L., Florence HLH consortium. et al. Isolated Full Donor T-Cell Chimerism After Haploidentical TCRαβ/CD19 Depleted HSCT Maintains Remission of Familial HLH. J Clin Immunol 44, 22 (2024). https://doi.org/10.1007/s10875-023-01612-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s10875-023-01612-6

Search

Navigation